{"entity":{"id":"nct05119907","kind":"trial","name":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","aka":[],"tldr":"A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan in Patients With Solid Tumor is a phase 2 interventional study registered as NCT05119907 by Gilead Sciences, with 53 participants enrolled, started 2021-10-12 and due to reach its primary completion in 2026-10. Interventions recorded: Sacituzumab Govitecan-hziy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05119907","url":"https://clinicaltrials.gov/study/NCT05119907"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05119907","phase":"2","setting":"A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor","sponsor":"Gilead Sciences","started":"2021-10-12","startedType":"actual","enrolled":53,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05119907/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}